Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Ritonavir, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Cleveland, Ohio

Conditions: Bronchopulmonary Dysplasia
Interventions: Infasurf surfactant (ONY, Inc.), Sham (No Treatment); Drug
Lead sponsor: Roberta Ballard; Other
Eligibility: 7 Days to 14 Days
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 21
States / cities: Little Rock, Arkansas • Berkeley, California • Oakland, California + 15 more

Conditions: Persistent Fetal Circulation Syndrome, Hypertension, Pulmonary, of Newborn, Persistent, Persistent Pulmonary Hypertension of Newborn
Interventions: Inhaled nitric oxide, Nitrogen Gas, Crossover iNO; Drug
Lead sponsor: University of Florida; Other
Eligibility: 30 Minutes to 48 Hours
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Blood Transfusion, Endothelial Physiopathology, Nitric Oxide, Pulmonary Hypertension
Interventions: Red blood Cells auto-transfusion, Inhaled Nitric Oxide (iNO) administration; Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions: Filgrastim, Cytarabine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 9
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 52
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 32 more

Conditions: COVID-19, Hypoxemia, Hypoxemic Respiratory Failure
Interventions: Inhaled nitric oxide (iNO), Nitrogen gas, Oxygen gas; Drug
Lead sponsor: Roger Alvarez; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 21 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 42 more

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 20 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 65
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 40 more

Conditions: HIV Infections
Interventions: Inosine pranobex; Drug
Lead sponsor: Newport Pharmaceuticals International; Industry
Eligibility: 18 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: HIV Infections
Interventions: Emivirine, Hydroxyurea, Delavirdine mesylate, Stavudine, Didanosine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: BRCA1/2 Mutation
Interventions: INO-5401, INO-9012, Cellectra 2000; Drug · Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Lamivudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 15 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 87
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 61 more

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 17 Years
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 76
States / cities: Birmingham, Alabama • Downey, California • La Jolla, California + 46 more

Conditions: Lymphatic Disease, HIV Infections
Interventions: Inosine pranobex; Drug
Lead sponsor: Newport Pharmaceuticals International; Industry
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: San Francisco, California • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions: Inhaled Nitric Oxide (iNO); Device
Lead sponsor: Third Pole Therapeutics, Inc.; Industry
Eligibility: 22 Years to 84 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Tampa, Florida • Cincinnati, Ohio • Charleston, South Carolina

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more

Conditions: HIV Infections
Interventions: Atazanavir, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 4
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 57
States / cities: Los Angeles, California • San Francisco, California • San Jose, California + 34 more

Conditions: HIV Infections
Interventions: Efavirenz, Emtricitabine, Stavudine, Didanosine; Drug
Lead sponsor: Triangle Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 51
States / cities: Birmingham, Alabama • Berkeley, California • Concord, California + 38 more

Conditions: Parkinson Disease
Interventions: Placebo, inosine; Drug
Lead sponsor: The Parkinson Study Group; Network
Eligibility: 30 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 16
States / cities: Los Angeles, California • Manchester, Connecticut • New Haven, Connecticut + 12 more

Conditions: Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: INOpulse®, Placebo, Long Term Follow Up; Combination Product
Lead sponsor: Bellerophon; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more

Search by objective public record fields.

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia

Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

iNOPulse for COVID-19

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy

A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)

A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma

Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease

A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Safety of Urate Elevation in Parkinson's Disease

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis